VA-LINEAGE-LOGISTICS
Lineage Logistics, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced the opening of its newest fully automated facility strategically located near the Port of Virginia’s world-renowned Virginia International Gateway in Portsmouth which offers an integrated network of highways, air, rail, and sea services.
The new state-of-the-art cold storage warehouse joins Lineage’s growing network of over 22 fully automated facilities worldwide. The Company’s growing automation presence comes at a critical time for the cold chain sector as the pandemic accelerated much-needed change to operations and systems within the decades-old cold storage industry. Lineage’s industry-leading automation technology increases storage density, maximizes capacity, provides real-time inventory management, and keeps food safe all while reducing energy consumption.
“As a testament to the power of public-private partnership, we are so pleased to announce the opening of our state-of-the-art facility in Portsmouth,” said Brian Beattie, Senior Vice President of Sale at Lineage Logistics. “Lineage’s innovative technology used in the Portsmouth warehouse will help our customers address rising supply chain demands both nationally and internationally while contributing to the ongoing economic development and job development in the region.”
Portsmouth Economic Development alongside the Virginia Economic Development Partnership, the Portsmouth Ports & Industrial Commission, and the Virginia Port Authority worked to secure the project for Lineage, which in the end resulted in the $84 million investment, produced over 80 high-paying jobs with a Portsmouth-first plan, and remediated a former chemical plant site that was previously vacant – all of which have benefited and will continue to support the city’s economic expansion.
“Portsmouth is thrilled to welcome Lineage Logistics to our business community,” said Shannon E. Glover, Mayor of Portsmouth. “Lineage has already become a wonderful community partner with its participation in our Portsmouth@Work programs, its commitment to supporting Portsmouth residents and businesses, and in the redevelopment of a key brownfield site. We look forward to Lineage continuing to grow in Portsmouth.”
The 167,264 square-foot facility, which is adjacent to the Virginia International Gateway, provides Lineage with access to key markets and will serve as a critical hub to connect people with food around the world. The facility will also aid in strengthening the supply chain and logistics infrastructure in Portsmouth as well as address the growing demand for cold storage in the region. The facility includes 26,000 pallet positions and blast freezing capabilities.
“This new cold storage facility is an important regional asset that is going to create jobs, provide greater flexibility to movers of cold cargo and help increase volumes of cold cargo moving across The Port of Virginia,” said Stephen A. Edwards, CEO and Executive Director of the Virginia Port Authority. “When we expanded and optimized Virginia International Gateway [just two years ago] we added a significant amount of capacity to handle cold cargo. Lineage’s new facility, which isn’t far from the gates at VIG, is going to help directly support our investment and make the port a destination for movers of cold cargo. We look forward to working with Lineage Logistics and helping to maximize its investment here.”
At 10:30 AM EST today, leaders from Lineage Logistics will be joined by Portsmouth community leaders and business partners, including Senator Louise Lucas, Secretary Brian Ball and Portsmouth Mayor Shannon Glover, to celebrate the hard work of the teams who transformed the facility from concept to reality. The event will include a ribbon-cutting ceremony, followed by group tours of the facility.
About Lineage Logistics
Lineage Logistics is the world’s largest temperature-controlled industrial REIT and logistics solutions provider. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 15 countries across North America, Europe and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network, and development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was listed as No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005235/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
